Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIR2DL5A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR2DL5A ECD-Fc / His Tag Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View KIR2DL5A Products |
| Gene Delivery | KIR2DL5A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for flow cytometry validation. |
View KIR2DL5A Products |
| Benchmark Ab | Anti-KIR2DL5A Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View KIR2DL5A Products |
| Validator | KIR2DL5A siRNA Set For knockdown verification in functional NK cell assays. |
View KIR2DL5A Products |
| Related Target A | PVR / CD155 Functional ligand for KIR2DL5A; key node in the TIGIT/DNAM-1 axis. |
View PVR Products |
| Related Target B | TIGIT Synergistic immune checkpoint sharing the PVR ligand; crucial for combination study. |
View TIGIT Products |
| Related Target C | KIR2DL5B Highly homologous sister isoform; essential for off-target counter-screening. |
View KIR2DL5B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| KIR Subfamily Off-Target Binding | KIR2DL5B and other KIR family homolog proteins strictly verified by mass spectrometry to guarantee screening specificity. |
| Conformational Integrity for Ligand Binding | HEK293 mammalian expression system preserves native post-translational glycosylation required for PVR interaction. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as positive controls. |
| False Positives in Cell Assays | Sequence-specific siRNA pool included for target knockdown validation. |
Live KIR2DL5A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIR2DL5A therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific NK-cell engagers (NKCEs) and combination therapies targeting the PVR-TIGIT-KIR2DL5A axis. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the inhibitory KIR2DL5A-PVR interaction to rejuvenate exhausted NK cells in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Innate Pharma, BMS | Advanced Solid Tumors, Hematological Malignancies | High-affinity binding assays (Need monomeric and dimeric KIR2DL5A ECD-Fc) |
| NK Cell Engager (NKCE) | Sanofi, Novelmed | Refractory Solid Tumors, AML | Multi-specific binding verification (Need stable cell lines via Lentivirus) |
| Combination Therapies (with anti-TIGIT) | Roche, Merck | NSCLC, Colorectal Cancer | Ligand competition assays (Need high-purity PVR and KIR2DL5A proteins) |